Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 17;67(1):e85.
doi: 10.1192/j.eurpsy.2024.1801.

Clustering and drivers of symptoms observed at week six after antidepressant treatment in depressed outpatients

Affiliations

Clustering and drivers of symptoms observed at week six after antidepressant treatment in depressed outpatients

Michel Danon et al. Eur Psychiatry. .

Abstract

Background: Depressive symptoms remaining after antidepressant treatment increase the risk of relapse and recurrence. We aimed to analyze the distribution and main drivers of remaining symptoms in patients with a major depressive episode.

Methods: Two independent samples of 8,229 and 5,926 patients from two large naturalistic studies were retrospectively analyzed. DSM-IV criteria for major depressive episodes were assessed during two face-to-face visits with clinicians: before the prescription of a new antidepressant, and after 6 weeks of treatment. The Hospital Anxiety and Depression Scale (HADS) was used to assess baseline severity of anxiety and depression.

Results: In both samples, two clusters of remaining symptoms were observed. The first cluster encompassed symptoms related to a negative emotional and cognitive bias and was specifically driven by the baseline severity of depression. The second cluster encompassed neurovegetative symptoms and was specifically driven by the baseline severity of anxiety.

Conclusions: The baseline anxiety-depressive balance of patients could be considered to adapt the treatment, focusing on emotional and cognitive symptoms with patients with high baseline severity of depression, and neurovegetative symptoms with patients with high baseline anxiety severity.

Keywords: anxiety; cognitive; depression; emotional; residual symptoms.

PubMed Disclaimer

Conflict of interest statement

PG received during the last 5 years fees for presentations at congresses or participation in scientific boards from Angelini, Janssen, Lundbeck, Otsuka, and Viatris. Other authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Schematic representation of a PCA of remaining depressive symptoms after 6 weeks of treatment in two independent samples (Sample 1, n = 7,809 and Sample 2, n = 5,473) and the role of depressive versus anxious symptoms as drivers of each cluster. β: standardized regression coefficients; DSM: Diagnostic and Statistical Manual of Mental Disorders; Ev: explained variance; HADS: Hospital Anxiety and Depression Scale; HADS-D*: prediction of factor 1 loading score (PCA) by depression baseline score (HADS) adjusted for anxiety baseline score (HADS), age, gender, length of current episode, number of past episodes and type of antidepressant treatment; HADS-A**: prediction of factor 2 loading score (PCA) by anxiety baseline score (HADS) adjusted for depression baseline score (HADS), age, gender, length of current episode, number of past episodes and type of antidepressant treatment; p: p value; PCA: Principal Component Analysis; s1: depressed mood (DSM-IV); s2: diminished interest (DSM-IV); s3: appetite disturbance (DSM-IV); s4: sleep disturbances (DSM-IV); s5: psychomotor disturbance (DSM-IV); s6: fatigue (DSM-IV); s7: worthlessness (DSM-IV); s8: diminished ability to think (DSM-IV); s9: suicidal thoughts (DSM-IV).

References

    1. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171–80. 10.1017/s0033291700033146. - DOI - PubMed
    1. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010;40:41–50. 10.1017/S0033291709006011. - DOI - PMC - PubMed
    1. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011;41:1165–74. 10.1017/S0033291710001911. - DOI - PubMed
    1. Zhou J, Zhou J, Feng Z, Feng L, Xiao L, Chen X, et al. Identifying the core residual symptom in patients with major depressive disorder using network analysis and illustrating its association with prognosis: a study based on the national cohorts in China. Gen Hosp Psychiatry 2024;87:68–76. 10.1016/j.genhosppsych.2024.01.012. - DOI - PubMed
    1. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011;28:137–44. 10.1002/da.20768. - DOI - PubMed

Substances